DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Provided By PR Newswire
Last update: May 13, 2025
Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation
Read more at prnewswire.com
